Genotyping in US clopidogrel label

Links shared publicly online about this topic.

2,027
total visits

Genotyping in US clopidogrel label

The label has been updated to include additional information on factors affecting patients' responses to the drug, including a new section on pharmacogenetics and advice that concomitant use of drugs that inhibit the CYP2C19 enzyme, such as omeprazole, should be discouraged.

View full resource at theheart.org

Tags: Stomach Ulcer Medication, Duodenal Ulcer Medication, Drug, Anti-Clotting Medication, Plavix, Iscover, Prilosec, Losec

Most Recently Shared on May 21, 2009 at 7:44 pm By:

Shelley Wood

heartwire: Genotyping info now in US clopidogrel label http://bit.ly/t6bBH

3 years ago...

Retweet

Favorite

Clopidogrel, genotyping, coronary stenting, and guidelines

blogs.theheart.org — “When we know that simple testing can tell us a lot about patient risk and there is a substantial data set to support testing, why do policy makers continue to ignore the importance of individualized medicine?” View full resource at blogs.theheart.org

Most Recently Shared on July 8, 2010 at 6:39 pm By:

Shelley Wood Cardiology

Clopidogrel, genotyping, coronary stenting, and guidelines with Dr Eric Topol. Calling for individualized medicine. http://bit.ly/aVZy3z

2 years ago...

Retweet

Favorite

FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug

fda.gov — “[03-12-2010] The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Plavix, the anti-blood clotting medication.” View full resource at fda.gov